FDA Approves Rybrevant plus Lazcluze for Patients with EGFR-Mutated Advanced Lung Cancer
Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approved Rybrevant®
(amivantamab-vmjw) plus Lazcluze™ (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions, or exon 21 L858R substitution mutations, as detected by an FDAapproved test.
- With this milestone, Rybrevant® plus Lazcluze™ becomes the first and only multitargeted,
chemotherapy-free combination regimen with demonstrated superiority versus osimertinib (Tagrisso®) for the first-line treatment of patients with EGFR-mutated NSCLC. - Rybrevant® is an EGFR- and MET*
- directed bispecific antibody that engages the immune system, and Lazcluze™ is a highly selective, brain-penetrant, third-generation oral EGFR TKI. Rybrevant® plus Lazcluze™ is the only regimen targeting both of the common EGFR mutations directly.
Source: Johnson & Johnson
